Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Lecznej
- Address
- Ul. Krasnystawska 52, 21-010 Leczna, Poland
Digestive System Diseases
The gastroenterology unit at Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Lecznej is exploring new oral therapies aimed at reducing persistent symptoms in celiac disease patients who continue to experience discomfort despite a gluten‑free diet.
- Assessment of novel capsule treatment for celiac disease
- Patient‑reported outcome measurement using symptom diaries
- Evaluation of mucosal healing in gluten‑sensitive individuals
Findings from these studies could lead to improved quality of life and better disease management for those affected.
Respiratory Tract Diseases
Researchers are examining the potential of an anti‑inflammatory antibody to protect patients with severe viral lung infection who require supplemental oxygen, aiming to lower the risk of death or progression to invasive ventilation.
- Safety and efficacy of targeted antibody therapy in viral pneumonia
- Impact on mortality and need for mechanical ventilation
- Integration with standard of care for oxygen‑dependent patients
The work supports the hospital’s commitment to advancing treatments for acute respiratory illnesses.
Skin and Connective Tissue Diseases
A cutting‑edge study at the site evaluates a bilayer engineered collagen graft, denovoSkin™, for its ability to accelerate closure and reduce scarring in individuals with deep partial‑ and full‑thickness burns compared with traditional skin grafting.
- Engineered skin substitute for severe burn injuries
- Comparison with standard split‑thickness skin grafts
- Assessment of wound healing speed and scar quality
Success could offer burn victims a faster recovery and improved cosmetic outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Lecznej
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo controlled, dose finding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2024-07-31 | 2024-07-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.